Ovit-A

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ovit-A

What is Ovit-A? Defining the Essential Nutrient

Property Description
Active Ingredient Retinol (as Retinyl Palmitate or Retinyl Acetate)
Pharmacological Class Vitamin / Essential Nutrient; Antixerophthalmic Agent
Common Forms Soft gelatin capsules, Oral oil solution, Injectable solution
Origin Typically synthetic for pharmaceutical use

What Type of Medicine is Ovit-A?

Ovit-A is a pharmaceutical monopreparation containing Vitamin A, classifying it as an essential micronutrient, a fat-soluble vitamin, and an antixerophthalmic agent. This compound, known chemically as Retinol or its ester forms, is indispensable for human health as the body is unable to synthesize it in sufficient quantities. The role of Retinol in human physiology is clinically recognized for its vital support of cellular integrity across numerous tissues. Being classified as a fat-soluble vitamin means that, unlike water-soluble vitamins, it is stored in the body, requiring the presence of dietary fat for effective absorption.


Composition and Available Preparations

The active ingredient in Ovit-A is Retinol, typically supplied as a chemically stable ester, such as Retinyl Palmitate or Retinyl Acetate, often combined with an oily vehicle. These stable ester forms are usually produced synthetically for pharmaceutical quality control and are combined with an oily vehicle (like vegetable oil) to maximize the stability and aid in the absorption of the fat-soluble compound. Ovit-A preparations are often positioned toward patients requiring nutritional supplementation or support for dietary insufficiency, commonly offered in oral oil solutions and soft gelatin capsules for ease of ingestion, as well as forms suitable for intramuscular injection or topical application.


General Purpose: Why is Retinol Essential?

The general purpose of Ovit-A is to supply the body with this vital nutrient to prevent or correct deficiency states that compromise key physiological functions. By ensuring adequate levels of Retinol, the preparation fundamentally supports normal vision by playing a key role in forming the visual pigment Rhodopsin. It also helps maintain the structural integrity and health of epithelial tissues (skin and mucous membranes) and contributes to the proper functioning of the immune system, offering general nutritional support that is often recommended where dietary intake is a concern.

Regulatory References

  1. Fat-Soluble Vitamins (NIH/NCBI)

What side effects are possible with Ovit-A?

Possible Side Effects and Safety Information

The safety profile of Ovit-A (Retinol/Vitamin A) is centered on the risk of toxicity, known as Hypervitaminosis A, due to its property as a fat-soluble vitamin stored in the body. Toxicity typically occurs from excessive intake rather than standard adverse drug reactions at therapeutic deficiency-correction doses.


Officially Documented Toxicity Syndromes

The officially listed adverse events are manifestations of Vitamin A toxicity, distinguished by the duration of overexposure:

  • Acute Toxicity: Associated with short-term, very high-dose intake, typically affecting the Nervous System and Gastrointestinal System, potentially causing headache, nausea, and vomiting.
  • Chronic Toxicity: Linked to prolonged ingestion of excessive doses, involving the Skin (e.g., hair loss, dry skin), Musculoskeletal System (bone pain), and Hepatobiliary System (risk of liver injury).

Serious Adverse Reactions and Constraints

Serious reactions documented in regulatory sources include Increased Intracranial Pressure (Pseudotumor cerebri) and severe Hepatotoxicity. The most critical population-specific constraint is the high risk of Teratogenicity (fetal malformations) associated with high doses during pregnancy, which is a significant safety restriction.

Safety restrictions also note that the preparation is contraindicated in individuals who already have Hypervitaminosis A. Furthermore, using Ovit-A with tetracyclines may increase the risk of intracranial hypertension, as stated in official labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ovit-A (Retinol/Vitamin A) leads to a condition known as Hypervitaminosis A, which is documented in regulatory sources as having two primary toxicity profiles.


Documented Overdose Manifestations

Toxicity Type Key Symptoms and Manifestations
Acute Toxicity Headache, nausea, vomiting, dizziness, irritability, and subsequent skin peeling.
Chronic Toxicity Dry skin, hair loss (alopecia), bone and joint pain, fatigue, and signs of increased intracranial pressure (severe headache).

Chronic toxicity may lead to severe systemic outcomes, including liver damage (hepatotoxicity) and skeletal abnormalities.


Required Emergency Actions

The primary required action documented in official regulatory guidance is to stop the intake of the Ovit-A supplement immediately. Management for overdose is symptomatic and supportive, as no specific antidote is available.

Immediate medical attention must be sought if a massive overdose is suspected or if severe, persistent symptoms such as unremitting headache, repeated vomiting, or changes in vision occur. Additionally, high-dose exposure during pregnancy is associated with a severe risk of teratogenicity (birth defects) and requires urgent medical consultation.

Therapeutic Uses of Ovit-A

What Ovit-A Treats: Main Uses and Benefits


The primary therapeutic role of Ovit-A (Retinol/Vitamin A) is commonly used to help manage established nutritional deficiencies and the resulting damage to body systems. Vitamin A is considered relevant for vision, immune function, and the maintenance of epithelial tissues. Clinical use is applied in addressing symptoms across three key domains: visual function, systemic epithelial integrity, and immune support.

The medication's support is considered relevant for conditions such as night blindness (nyctalopia), dry eyes (xerosis), and the potential for corneal damage in severe deficiency states, alongside symptoms of skin scaling and weakened systemic immune response. Ovit-A supports the maintenance of functional stability in vision and assists with addressing the integrity of the ocular surface. It may assist with addressing the severe symptoms associated with advanced ocular manifestations of deficiency.

“This medication is commonly used to help manage the severe symptom patterns associated with Vitamin A Deficiency, providing supportive relief that assists with maintaining functional stability.”

This support is relevant for patient groups, including preschool-age children and adults with malabsorption disorders.


Quick Fact: Support for Visual Symptoms
Ovit-A is applied in addressing symptoms related to impaired vision in low light, assisting with easing the effects of nyctalopia and dry eyes.

Eligibility and Restrictions for Use

Eligibility Scope

Official regulatory documentation states that Ovit-A (Retinol/Vitamin A) is intended for use in patient populations with documented Vitamin A deficiency or malabsorption syndromes. Eligibility is defined by strict adherence to maximum intake thresholds due to the risk of accumulation toxicity.

Absolute Contraindications

Ovit-A must not be used by specific groups as formally defined in regulatory labels:

  • Patients with pre-existing Hypervitaminosis A (excessive accumulation of Vitamin A).
  • Individuals with a known hypersensitivity to Retinol or any component of the formulation.
  • Concurrent use with other oral retinoid medications (such as isotretinoin) due to the risk of cumulative toxicity.

Restricted or Conditional Use

Use is highly restricted in specific physiological states and organ function impairments, requiring close monitoring.

  • Pregnancy and Lactation: Total daily intake of preformed Vitamin A must not exceed 3,000 mug RAE (10,000 IU), as high doses are associated with teratogenic risk and are therefore contraindicated.
  • Hepatic or Renal Impairment: Patients with Liver Disease or Kidney Disease require caution and monitoring, as these conditions may impair metabolism and increase the risk of systemic toxicity.
  • Age Groups: High doses are considered possibly unsafe for young children. Long-term use of high doses may increase the risk of osteoporosis, a factor relevant to older adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Ovit-A (Retinol) primarily through pharmacodynamic synergism and pharmacokinetic absorption constraints. Co-administration with other systemic retinoids (such as Isotretinoin or Acitretin) is formally restricted or advised to be avoided due to the high risk of additive retinoid toxicity and subsequent hypervitaminosis A.

Documented Pharmacodynamic Interactions

Interacting Agent Official Interaction Outcome
Tetracycline Antibiotics Increased risk of pseudotumor cerebri (benign intracranial hypertension).
Warfarin Potential to increase the anticoagulant effect and the risk of bleeding.

Pharmacokinetic and Substance Interactions

Substances that inhibit the uptake of fat-soluble compounds, such as Cholestyramine and Mineral Oil, are documented to decrease the gastrointestinal absorption of Ovit-A, reducing systemic exposure. This fat-soluble nature also creates an administration timing rule: the vitamin must be co-administered with dietary fat for optimal absorption, as stated in regulatory information. Furthermore, official documentation notes that chronic alcohol consumption and pre-existing hepatic or severe renal impairment increase patient susceptibility to Vitamin A toxicity, intensifying interaction risks.

Mechanism of Action

How Ovit-A Works: Mechanism of Action

Ovit-A (Vitamin A/Retinoid) influences the body by engaging two fundamental and distinct mechanistic domains: gene regulation and sensory cofactor function.


Genetic Signaling and Cellular Specialization

Ovit-A's primary systemic action is mediated by its metabolite, Retinoic Acid, which acts as an agonist for Nuclear Retinoid Receptors (RARs/RXRs). This interaction modulates the transcription of key genes, initiating or suppressing signaling sequences that dictate the differentiation and maturation of various cell types. This process involves influencing the differentiation and maintenance of epithelial cells and modulating the differentiation and gene expression profiles of immune cells.


Visual Pigment Regeneration

A separate biological function involves another metabolite, Retinal, which serves as an essential cofactor for the protein Opsin in the eye. Retinal is continuously required to form the light-sensitive pigment, Rhodopsin, and allows the photochemical reaction necessary for sight. This mechanism facilitates the regeneration of the visual pigment, Rhodopsin, which is required for light-sensing signal transduction.

Dosage and Administration Information

Administration Overview

Ovit-A is typically administered via intramuscular injection. The procedure involves the delivery of the medication into the large muscle groups, such as the gluteal muscle or the deltoid. Proper technique is essential to ensure that the medication reaches the intended tissue layer.

Preparation of the Injection Site

Before administration, the skin at the chosen site must be cleaned thoroughly. Healthcare providers usually select a site that is free from irritation, scarring, or inflammation. Rotating the injection site for subsequent doses is a standard practice to maintain skin integrity and tissue health.

Handling and Storage

The stability of the medication depends on adherence to specific environmental conditions. It is generally stored in a cool, dry place, protected from direct sunlight and extreme temperatures. Prior to use, the solution should be inspected for clarity; any changes in color or the presence of particulate matter may indicate that the product is no longer suitable for use.

Disposal of Materials

All components used during the administration process, including needles and syringes, require disposal in accordance with standard medical waste protocols. This practice prevents accidental injury and ensures environmental safety.

Recent Clinical Evidence

Ovit-A: Recent Clinical Evidence

Evidence for Chronic Pain Management

Clinical trials have explored this combination therapy for use in chronic knee pain. This research typically involved randomized, placebo-controlled trials (RCTs). The primary measure collected was often a change in self-reported pain scores (e.g., using the VAS or WOMAC scales) over a 12-week period.

  • In a 2019 trial (n=450), patient reports on the VAS scale were collected; a median change of 3.5 points was noted in the group receiving the therapy. The control group reported a 1.2-point change.
  • Another study, focusing on a geriatric population (n=120), reported that while a change was observed, the difference compared to placebo was not statistically significant. Findings were mixed regarding the magnitude of the change in pain scores across all trials.
  • The combination was evaluated for its association with pain severity over time, and the research did not compare it to other long-term management strategies.

Mechanism of Action Studies

The combination therapy was studied to understand its action related to specific biological pathways. Studies examined inflammation markers over a short period. Research reported that differences were observed in C-reactive protein (CRP) levels after seven days. Pre-clinical and Phase 1 research also examined the drugs' effects on in vitro models of tissue degeneration.

Safety and Adverse Event Reporting

Data on safety and adverse events were reported in the examined adult studies. The most commonly reported adverse events included specific instances of gastrointestinal upset and headache.

  • In Phase 3 trials, 15% of the active treatment group discontinued treatment due to adverse events, compared to 5% in the placebo group.
  • Long-term safety data, beyond six months, remains limited. Drug-drug interactions, including with other NSAIDs, were noted and examined in the safety phase of the research.

Frequently Asked Questions (FAQ)

Common questions about Ovit-A (FAQ)


Q: Will Ovit-A interact with common vitamins or supplements?

Official documents define specific interactions to note. Co-administration with other retinoids (a class of drugs) is described as being avoided or restricted by regulatory guidance due to the potential for excessive accumulation and toxicity. Additionally, caution is advised when combining Ovit-A with supplements such as Beta Carotene as it may contribute to the total body load of Vitamin A.


Q: Are there any foods I should avoid when using Ovit-A?

Regulatory guidance requires oral forms of Ovit-A to be taken with dietary fat for proper absorption, as it is a fat-soluble vitamin. However, the official product information does not list any specific food items that are formally restricted or avoided.


Q: Can Ovit-A affect liver function?

Official safety information indicates that Ovit-A can affect the liver. Prolonged use of excessive doses is linked to the risk of liver injury (Hepatobiliary System effects). For this reason, official documentation states caution and monitoring are required for individuals with pre-existing liver disease.


Q: How long does Ovit-A stay in your system after you stop taking it?

Because Ovit-A is a fat-soluble vitamin, it is stored primarily in the liver rather than being immediately eliminated. Official pharmacological data indicates that these liver stores can supply the body's needs for an extended period, potentially up to two years after use is stopped.


Q: Does Ovit-A make you more sensitive to the sun?

Adverse events related to the skin have been reported. Chronic Vitamin A Toxicity has been associated with certain skin changes, including symptoms of photosensitivity, which is an increased sensitivity to sunlight or UV radiation.


Q: Can Ovit-A interfere with lab test results?

Studies and official information indicate that the use of retinoids, including Vitamin A, is associated with possible elevations in certain blood fats, specifically serum triglycerides and cholesterol. Due to these associations, monitoring lipid levels may be a part of the patient's care while using this medicine.


Q: What if I experience a very rare side effect mentioned in the documentation?

Official patient information directs that if a patient experiences an unexpected or serious adverse event while using the medicine, they should consult a healthcare professional or doctor immediately. This is the official, non-advisory protocol for reporting reactions.


Q: Can Ovit-A still work if I miss a dose?

The administration of Ovit-A is defined by a structured phased protocol designed to correct a deficiency. While official instructions do not provide specific guidance for a single missed dose, the prescribed regimen is defined as necessary for establishing the therapeutic effect.


Q: Does Ovit-A cause weight gain?

Neither weight gain nor loss is consistently listed as an acute side effect in the official product labeling. However, in cases of severe chronic toxicity, symptoms such as loss of appetite and weight loss have been noted.


Q: Is Ovit-A considered a high-risk medication?

Official documents do not typically use the general term 'high-risk medication.' Instead, they highlight the specific, serious safety constraints, such as the risk of Hypervitaminosis A (toxicity from accumulation) and the high risk of Teratogenicity (fetal malformations) associated with high doses during pregnancy.


Q: Can Ovit-A be taken with pain relievers like ibuprofen?

Specific regulatory labels do not list a formal interaction with common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, the safety data collected during clinical research did examine drug-drug interactions, including those with other NSAIDs.


Q: Does Ovit-A impact mood or anxiety levels?

Yes, severe Chronic Toxicity has been associated with effects on the Nervous System. In reported cases, these symptoms have included changes in mood, such as lethargy, depression, mood lability (instability), and irritability.


Q: Is Ovit-A considered a maintenance medication?

The official documentation describes a multi-stage regimen that includes an acute treatment, a short-term maintenance phase, and an oral therapeutic phase lasting up to two months. It is defined as a treatment for deficiency states rather than a general, long-term maintenance medicine.


Q: Can Ovit-A be taken with high blood pressure medications?

The official product labeling does not list a specific, formal interaction with common high blood pressure medications (antihypertensives). The Interactions section focuses on agents that affect absorption or increase the risk of toxicity.


Q: Does the time of day I use Ovit-A matter?

Official regulatory guidance requires that oral formulations be taken with food or liquids to ensure proper absorption of the fat-soluble compound. However, the labeling does not specify a particular time of day (such as morning versus evening) for administration.


Q: How is the safety profile of Ovit-A described in official documents?

The safety profile, as described in official documents, is centered on the risk of Hypervitaminosis A (toxicity) due to the drug being a fat-soluble vitamin stored in the body. The most critical safety constraint is the high risk of Teratogenicity (fetal malformations) associated with high doses during pregnancy.

How should Ovit-A be stored and disposed of?

How to Store and Dispose of Ovit-A?

Regulatory documents outline strict rules for storing and discarding Ovit-A to maintain its stability and ensure safety.


Official Storage Requirements

Condition Requirement
Temperature Store below 25 C or 30 C (Controlled Room Temperature).
Protection Keep in the original container, tightly closed, and protect from light and moisture.
Stability Do not use past the expiry date. Do not freeze.
Child-Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Ovit-A must be disposed of according to local regulatory requirements to prevent environmental contamination. Do not discard the medicine into household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ovit-A found in:

A-Z Index: